Biomarin Pharmaceutical Inc BMRN:NASDAQ

Last Price$76.50NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/16/19
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$74.97 (1)
Ask (Size)$78.41 (1)
Day Low / HighN/A - N/A
Volume1.9 M
 

View Biotechnology IndustryPeer Comparison as of 08/16/2019

 

Biomarin Pharmaceutical Inc ( NASDAQ )

Price: $76.50
Change: +4.77 (6.65%)
Volume: 1.9 M
4:00PM ET 8/16/2019
 
 

Seattle Genetics Inc ( NASDAQ )

Price: $79.20
Change: +2.49 (3.25%)
Volume: 548.7 K
3:59PM ET 8/16/2019
 
 

Exact Sciences Corp ( NASDAQ )

Price: $119.82
Change: +1.60 (1.35%)
Volume: 1.9 K
4:00PM ET 8/16/2019
 
 

Ionis Pharmaceuticals Inc ( NASDAQ )

Price: $69.08
Change: +1.60 (2.37%)
Volume: 600.00
4:00PM ET 8/16/2019
 
 

Incyte Corp ( NASDAQ )

Price: $83.12
Change: +2.51 (3.11%)
Volume: 1.1 M
3:59PM ET 8/16/2019
 

Read more news Recent News

2020 Earnings Forecast for BioMarin Pharmaceuticals Targeted Higher
11:41PM ET 8/16/2019 MT Newswires

The 2020 forecasted earnings estimate for BioMarin Pharmaceuticals' (NASDAQ:BMRN, Recent Price: 76.50) for the year ending December 31, 2020 has been...

2020 Earnings Estimate for BioMarin Pharmaceuticals Lowered
12:31AM ET 8/13/2019 MT Newswires

The 2020 forecasted earnings estimate for BioMarin Pharmaceuticals' (NASDAQ:BMRN, Recent Price: 73.59) for the year ending December 31, 2020 has been...

Earnings Forecast for BioMarin Pharmaceuticals in 2020 Raised
2:11AM ET 8/08/2019 MT Newswires

The December 31, 2020 forecasted earnings estimate for BioMarin Pharmaceuticals (NASDAQ:BMRN, Recent Price: 76.69) has been increased. The current...

BioMarin Pharmaceuticals' Q3 and 2019 Estimates Increased but 2020 Earnings Number Slips
11:31PM ET 8/05/2019 MT Newswires

BioMarin Pharmaceuticals' (NASDAQ:BMRN, Recent Price: 76.02) consensus estimates for Q3 ending September 30, 2019, and the full year forecasts for 2019 and...

Company Profile

Business DescriptionBioMarin Pharmaceutical, Inc. is a biotechnology company, which develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its products include Aldurazyme, Brineura, Kuvan, Naglazyme, Palynziq and Vimizim. The company was founded by Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA. View company web site for more details
Address770 Lindaro Street
San Rafael, California 94901
Phone+1.415.506.6700
Number of Employees2,849
Recent SEC Filing08/08/20194
Chairman & Chief Executive OfficerJean-Jacques Bienaimé
Chief Financial Officer & Executive Vice PresidentDan Spiegelman
Chief Information OfficerEduardo E. Von Pervieux
Chief Medical Officer & Senior Vice PresidentGeoffrey M. Nichol

Company Highlights

Price Open$72.51
Previous Close$76.50
52 Week Range$71.53 - 106.74
Market Capitalization$13.7 B
Shares Outstanding179.5 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement10/24/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.51
Beta vs. S&P 500N/A
Revenue$1.5 B
Net Profit Margin-7.24%
Return on Equity-3.74%

Analyst Ratings as of 08/09/2019

Buy
18
Overweight
1
Hold
6
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset